Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836426 | 0.94 | ADRA2A (0.47) | LMNAMAPK1ADRA2AADRA2BADRA2C | |
| SCHEMBL6837758 | 0.92 | ADRA2A (0.51) | LMNAMAPK1ADRA2AADRA2BADRA2C | |
| SCHEMBL6836498 | 0.91 | ADRA2A (0.51) | LMNAMAPK1ADRA2AADRA2BADRA2C | |
| SCHEMBL6837770 | 0.90 | ADRA2A (0.49) | LMNAMAPK1ADRA2AADRA2BADRA2C | |
| SCHEMBL6837596 | 0.87 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CKMT2AHTT | |
| SCHEMBL6837951 | 0.86 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CKMT2AALDH1A1 | |
| SCHEMBL6837950 | 0.86 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CKMT2AHTT | |
| SCHEMBL6837903 | 0.85 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CKMT2AALDH1A1 | |
| SCHEMBL6836425 | 0.83 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CKMT2AHTT | |
| SCHEMBL6836666 | 0.83 | ADRA2A (0.57) | LMNAADRA2AADRA2BADRA2CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716987-B1 | PHOSPHODIESTERASE IV INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | LMNA 1848/4885MAPK1 2021/4885ADRA2A 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.